Glurenorm

Glurenorm is an oral tablet containing the sulfonylurea gliquidone; the specific strength is not disclosed in the available data. It is a prescription medication marketed in the European Union for the management of type 2 diabetes mellitus. As a second‑generation sulfonylurea, Glurenorm works by stimulating insulin release from pancreatic β‑cells. It belongs to ATC code A10BB04 and is classified as an oral hypoglycemic agent.

Glurenorm (gliquidone) is indicated for the treatment of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient to achieve glycemic control. It may be used as monotherapy or in combination with other antidiabetic drugs as part of a comprehensive management plan. - Initiate therapy in adults with inadequate glycemic control. - Add to metformin when monotherapy does not achieve target HbA1c. - Combine with basal insulin for patients requiring intensified treatment. - Use in patients with preserved pancreatic β‑cell function. - Adjust dose based on renal function and hypoglycemia risk.

The safety profile of Glurenorm reflects the typical effects of second‑generation sulfonylureas, with both frequent mild reactions and rarer serious events. Common: - Mild hypoglycemia, especially with missed meals. - Nausea or abdominal discomfort. - Headache or dizziness. - Weight gain due to increased insulin activity. - Diarrhea. Serious: - Severe hypoglycemia leading to loss of consciousness. - Allergic skin reactions such as rash or urticaria. - Hepatic dysfunction indicated by elevated transaminases. - Hematologic abnormalities like leukopenia or thrombocytopenia. - Pancreatitis.

When prescribing Glurenorm, clinicians should evaluate patient-specific factors that may increase the risk of adverse outcomes or reduce therapeutic effectiveness. - Assess renal and hepatic function before initiation and during therapy. - Use caution in elderly patients due to heightened hypoglycemia susceptibility. - Avoid use in patients with known sulfonylurea hypersensitivity. - Monitor blood glucose closely during periods of fasting or altered diet. - Adjust dose or discontinue if recurrent hypoglycemia occurs. - Counsel patients on recognizing early signs of low blood sugar. - Consider pregnancy status; safety data are limited.

Glurenorm can interact with several medicines that affect glucose metabolism or sulfonylurea clearance, potentially altering its efficacy or safety. Avoid: - Concurrent use with other sulfonylureas or meglitinides. - Strong CYP2C9 inhibitors such as fluconazole or amiodarone. - High‑dose aspirin or NSAIDs that may potentiate hypoglycemia. Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can increase blood glucose levels. - Anticoagulants like warfarin, requiring INR monitoring.